/
Infectious Disease
HIV Infections
27
Pipeline Programs↗
60
Active Trials↗
10
Companies Involved↗
HIV Infections is an emerging landscape with 27 programs across 10 companies. The most active players are GSK, Gilead. 13 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 19
Phase 313
Approved
No programs
Analysis
Modality Breakdown
65%
Small molecule
11 of 17 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 81% of 27 pipeline programs.
Analysis
Trial Status
85
clinical trials
Recruiting24 · 28%
Completed24 · 28%
Active, not recruiting22 · 26%
Not yet recruiting13 · 15%
Enrolling by invitation1 · 1%
Terminated1 · 1%
Clinical Trials
Trial Activity
85 trials
A Phase 1 Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT06665646·40 enrolled
A Long-term Follow-up Study for HIV-infected Individuals Who Have Participated in HIV-NAT Study Protocols
Recruiting·TThe HIV Netherlands Australia Thailand Research Collaboration·N/A·NCT00411983·10,000 enrolled
RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV): Safety and Efficacy of Broadly Neutralizing Antibodies Combined With Therapeutic Vaccination for the Induction of HIV Remission
Recruiting·HHenry M. Jackson Foundation for the Advancement of Military Medicine·Phase 1·NCT06484335·48 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)